Rituximab effectively reduced skin sclerosis and appeared to have a beneficial effect on interstitial lung disease (ILD) for patients with systemic sclerosis (SSc) in a randomized, clinical trial. At ...

Please provide your email address to receive an email when new articles are posted on . Rituximab was associated with significant improvements in both skin and lung parameters over long-term follow-up ...

Artificial intelligence (AI) is shaping the future of health care, offering new tools for earlier diagnosis of disease and more precise tracking of treatment outcomes. In a new Yale-led study, ...

Systemic sclerosis — or scleroderma that affects the skin and internal organs -, is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the United ...

High serum type I interferon (IFN) scores, measured through six chemokines, correlated with poorer lung function and health-related quality of life in patients with diffuse cutaneous systemic ...